TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07361497: ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent

Sponsor: Bristol-Myers Squibb · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 850 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07361497 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07361497 Rescue Dossier →